Compare RCON & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RCON | TVGN |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Blank Checks |
| Sector | Energy | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 21.3M |
| IPO Year | 2008 | 2021 |
| Metric | RCON | TVGN |
|---|---|---|
| Price | $0.90 | $6.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 113.0K | 4.9K |
| Earning Date | 09-30-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,430,788.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.02 | $0.14 |
| 52 Week High | $6.42 | $32.90 |
| Indicator | RCON | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 44.94 |
| Support Level | $0.79 | $6.15 |
| Resistance Level | $1.04 | $7.65 |
| Average True Range (ATR) | 0.11 | 0.49 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 13.29 | 41.53 |
Recon Technology Ltd provides automation systems, industrial equipment, and support services tailored for the oil and gas industry in China. The company's business spans key segments such as automation products and software, equipment and accessories, oilfield environmental protection, and platform outsourcing services. It generates the majority of its revenue by providing integrated automation services to Chinese petroleum companies at oilfields. Its key products and services include pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system. The company's operations are centered on servicing upstream clients throughout China, with some broader industrial automation solutions.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.